[Evolution of antimicrobial resistance against Pseudomonas aeruginosa in a French university hospital between 2002 and 2006]

Pathol Biol (Paris). 2010 Feb;58(1):1-6. doi: 10.1016/j.patbio.2009.08.002. Epub 2009 Oct 28.
[Article in French]

Abstract

Aim of study: Monitor evolution of antibiotic resistance of Pseudomonas aeruginosa from 2002 to 2006 in our hospital to optimize antibiotherapy.

Patients and method: The infections/colonizations with P. aeruginosa have been identified by the hospital's informatic database. Bacteriological samples realized 48hours after patient's admission was considered as nosocomial. A Cochran-Armitage test was conducted to assess the evolution of resistance.

Results: During this period, 2098 infections/colonizations with P. aeruginosa have been identified. Bacteriological samples (68.5%) were nosocomial. Among the beta-lactam antibiotics, ceftazidime and imipenem were the most active (R=16.8% and 15.2%, respectively), followed by piperacillin and piperacillin-tazobactam (R=24.8%, 18.4%, respectively). Amikacin and tobramycin were more active than gentamicin (R=19.9%; 22.2% and 40.6%, respectively). 28.9% of strains were resistant to ciprofloxacin. Nosocomial strains were significantly more resistant than non-hospital strains: ceftazidime: 17.9% versus 14.2%, p=0.0346; ticarcillin-clavulanic acid: 47.5% versus 39.6%, p=0.0009; piperacillin-tazobactam: 20.0% versus 14.8%, p=0.0046; ciprofloxacin: 30.7% versus 25.2%, p=0.0112. A significant increase in the resistance of nosocomial strains to ceftazidime, ticarcillin-clavulanic acid and piperacillin-tazobactam was noted. Resistance from non-hospital strains to fluoroquinolones, aminoglycosides, ceftazidime, piperacillin and ticarcillin-clavulanic acid decreased significantly.

Conclusion: P. aeruginosa is a predominantly nosocomial microorganism. There is a decrease of resistance for non-hospital strains. But the resistance of nosocomial strains to antibiotics widely prescribed in hospital is worrying.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Cross Infection / epidemiology
  • Cross Infection / microbiology*
  • Drug Resistance, Multiple, Bacterial*
  • France / epidemiology
  • Hospitals, University / statistics & numerical data*
  • Humans
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents